|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0020792,
umls-concept:C0025914,
umls-concept:C0026809,
umls-concept:C0085358,
umls-concept:C0282580,
umls-concept:C0302600,
umls-concept:C0598934,
umls-concept:C1332717,
umls-concept:C1334306,
umls-concept:C1413244,
umls-concept:C1706438,
umls-concept:C2698600
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2005-12-20
|
|
pubmed:abstractText |
Vascular endothelial growth factor receptor 2 (VEGFR2/KDR) plays a crucial role in tumor-associated angiogenesis and vascularization. It has been established that monoclonal antibodies against VEGFR2 can inhibit angiogenesis. In this study, two naturally processed CD8 T-cell epitopes (VILTNPISM and FSNSTNDILI) were identified from murine KDR. Cytotoxic T lymphocytes targeting endothelial cells could be directly monitored by KDR2 and KDR3 Elispots or major histocompatibility complex class I tetramer staining. Immunization with these two peptides effectively reduced angiogenesis and inhibited tumor growth in mouse models. Thus, vaccination with KDR peptides alone or in combination with other anti-angiogenesis agents may afford a novel immunotherapy for inhibition of tumor growth.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1524-9557
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
32-40
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:16365598-Animals,
pubmed-meshheading:16365598-CD8-Positive T-Lymphocytes,
pubmed-meshheading:16365598-Cancer Vaccines,
pubmed-meshheading:16365598-Cell Line,
pubmed-meshheading:16365598-Epitopes, T-Lymphocyte,
pubmed-meshheading:16365598-H-2 Antigens,
pubmed-meshheading:16365598-Immunohistochemistry,
pubmed-meshheading:16365598-Mice,
pubmed-meshheading:16365598-Neoplasms,
pubmed-meshheading:16365598-Neovascularization, Pathologic,
pubmed-meshheading:16365598-Peptides,
pubmed-meshheading:16365598-Vascular Endothelial Growth Factor Receptor-2
|
|
pubmed:articleTitle |
Identification of H-2Db-specific CD8+ T-cell epitopes from mouse VEGFR2 that can inhibit angiogenesis and tumor growth.
|
|
pubmed:affiliation |
The Vaccine Branch, The Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20889, USA.
|
|
pubmed:publicationType |
Journal Article
|
